Background:Acinetobacter baumannii, is an emerging nosocomial multidrug resistance pathogen with the rapid spread of clones being reported in health-care settings and hospitals worldwide. Carbapenem resistance in this bacterium has been attributed to D OXA β-lactamases with OXA-51-like β-lactamase, being present in all A. baumannii isolate. The present study looks into the antibiotics susceptibility and molecular characterization of clinical A. baumannii isolates from Intensive Care Unit (ICU) samples in Al-Hofuf, South-eastern region of Saudi Arabia.Materials and Methods:Eleven strains of ICU A. baumanni i isolates were used for the investigation. Bacteria isolation was by basic microbiological techniques. Organisms identification and antibiogram susceptibility testing was by the BioMerieux VITEK 2 compact automated system (BioMerieux, Marcy I'Etoile France), according to the manufacturers guidelines. Confirmation of A. baumannii was by the presence of the OX-51 gene, also, carbapenemase encoding resistant genesblaOXA-23, blaOXA-40, and blaOXA-51, were analyzed using multiplex PCR. The Student's t test was used to analyze the obtained data for between group comparisons with statistically significance level set at P < 0.05.Results:Eight of the isolates were confirmed to be A. baumannii. Five of which were resistant to the carbapenems against which they had been tested. One isolate was resistant to tigecycline, whereas three tested intermediate to the drug. OXA-23 was detected in isolates 1, 4, 5, 6, and 7.Conclusion:It can, therefore, be concluded that the probable predominate carbapenems resistant genes in ICU isolates from the present investigation, are those associated with OXA-23.

Introduction: Management of dyslipidemia is an important part of most practice guidelines with many variations between these guidelines. Unfortunately, usually these guidelines are not followed widely on the level of primary care, possibly due to insufficient qualification of health care staff in primary care, non-participation in recent guidelines, and unrealistic target assigned to patients that leads them to non-compliance with medication and follow-up. Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 2001, through February 2017. The following search terms were used: dyslipidemia, primary health care dyslipidemia management, follow-up of dyslipidemia. Aim: In this review, we aimed at evaluating the management expected from primary health care for risk assessment, treatment and follow-up of patients with dyslipidemia. Conclusion: Many guidelines exist for the proper management of dyslipidemia in the primary care setting. Screening is crucial for preventing the cardiovascular sequelae of dyslipidemia. Management modalities include lifestyle modification and pharmacotherapy, while the significance of follow-up cannot be neglected.